



Alpa Laboratories Ltd.

33/2, Pigdamber A.B. Road - 453 446 Distt. Indore - (M.P.) India

Phone No. : +91-731- 429 4567 Fax No. : +91-731- 429 4444

Email : mail@alpalabs.in

CIN : L85195MP1988PLC004446

Date:-31st July, 2020

The Bombay Stock Exchange Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 Scrip Code:532878	National Stock Exchange of India Ltd. Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai - 400 051 Scrip Code:ALPA
---	--

Sub: Declaration in respect of Unmodified Opinion on Audited Financial Statement for the Financial Year ended March 31, 2020.

Pursuant to Regulation 33 (3)(d) of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015 we hereby declare and confirm that the statutory auditor of the Company viz., Anuradha Ratnaparkhi & Associates., Chartered Accountant, have issued on Unmodified Audit Report on Standalone and Consolidated Financial Statements of the Company for the year ended March 31, 2020.

Kindly take the above information on record.

Thanking You

Yours Faithfully.

For ALPA LABORATORIES LIMITED


**MEGHA NEEMA
COMPANY SECRETARY**



ALPA LABORATORIES LIMITED

Financial Results for Quarter and Financial Year ended 31st March 2020

33/2 PIGDAMBER, A.B. ROAD, RAU
INDORE (M.P.) 453446

(Rs. in lacs except EPS)

I. Statement of Profit and Loss - Standalone					
Particulars	Standalone Results				
	Quarter Ended			Year Ended	
	Mar-20	Dec-19	Mar-19	Mar-20	Mar-19
	Audited	Unaudited	Unaudited	Audited	Audited
1. Income					
a) Revenue from operations	1,816.28	2,412.64	1,909.42	8,596.91	7,798.80
b) Other Income	76.99	116.41	238.05	296.67	506.52
Total income from operations	1,893.27	2,529.05	2,147.47	8,893.58	8,305.32
2. Expenses					
a) Cost of materials consumed	901.75	1,230.82	1,130.96	4,948.01	4,645.84
b) Purchases of stock-in-trade	78.67	20.75	26.26	193.83	84.66
c) Changes in inventories of finished products, work in progress and stock in trade	(124.93)	184.32	171.56	(42.41)	152.61
d) Employee benefit expenses	329.13	292.28	382.55	1,182.43	1,204.10
e) Finance costs	3.69	2.81	6.90	19.94	56.87
f) Depreciation and amortization expense	33.16	28.68	24.31	114.20	109.57
g) Other expenses					
Manufacturing & Operating	106.92	105.04	111.43	427.09	425.80
Others	641.64	355.29	391.58	1,542.76	1,163.65
Total expenses	1,970.02	2,219.99	2,245.55	8,385.85	7,843.09
3. Profit/(Loss) before exceptional items and tax (1-2)	(76.75)	309.06	(98.08)	507.73	462.23
4. Exceptional Items	-	-	-	-	-
5. Profit/ Loss(-) before tax (3+/-4)	(76.75)	309.06	(98.08)	507.73	462.23
6. Tax (Expenses)/ Benefit					
Current tax	(190.00)	-	(125.00)	(190.00)	(125.00)
Deffered Tax	75.48	-	(59.02)	75.48	(59.02)
Tax Related to Earlier Years	14.60	-	18.72	14.60	16.71
7. Profit/ Loss(-) for the period (5-/+6)	(176.67)	309.06	(263.38)	407.81	294.92
8. Other Comprehensive Income					
(i) (a) Items that will not be reclassified to profit or loss	0.31	0.50	(6.73)	2.49	(6.60)
(b) Tax expense/(benefit) on items that will not be reclassified to profit or loss	-	-	-	-	-
(ii) (a) Items that will be reclassified to profit & loss	-	-	-	-	-
(b) Tax expense/(benefit) on items that will be reclassified to profit or loss	-	-	-	-	-
Total Other comprehensive (loss)/ income (net of tax)	0.31	0.50	(6.73)	2.49	(6.60)
9. Total comprehensive income for the period	(176.35)	309.57	(270.11)	410.30	288.32
10. Paid-up equity share capital (Face Value Rs. 10 Each)	2,104.06	2,104.06	2,104.06	2,104.06	2,104.06
11. Other equity (excluding revaluation reserve)				8,918.90	8,508.60
12. Debenture Redemption Reserve					
13. Basic and Diluted Earnings per share after extraordinary items (not annualized)	(0.84)	1.47	(1.28)	1.95	1.37

Notes -

- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, read with rule 3 of the Companies (Indian accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Accounting Rules, 2016
- The Company is operating in the single segment of Drugs & Chemicals.
- The Figures of Previous Year/ Periods may have been regrouped/reclassified/restated wherever necessary.
- Stock Market had crashed in the month of March, 2020. As a result, NAV's of mutual funds had also fallen sharply as on the Balance sheet date resulting in significant loss of fair value of mutual funds amounting to 271.03 lakhs for the quarter ending 31st March, 2020 and 248.87 lakhs for the year ending 31st March, 2020.
- The statement includes the results for the quarter ended 31st March 2020 being the balancing figure between audited figures in respect of the full financial year and the published year to date figure upto the third quarter of the current financial year which were subject to limited review by the auditors.

For ALPA LABORATORIES LIMITED

Megha Neema
MEGHA NEEMA
COMPANY SECRETARY AND COMPLIANCE OFFICER

ALPA LABORATORIES LIMITED

Financial Results for Quarter and Financial Year ended 31st March 2020

33/2 PIGDAMBER, A.B. ROAD, RAU

INDORE (M.P.) 453446

(Rs. in lacs except EPS)

II. Statement of Profit and Loss - Consolidated					
Particulars	Consolidated Results				
	Quarter Ended			Year Ended	
	Mar-20	Dec-19	Mar-19	Mar-20	Mar-19
	Audited	Unaudited	Unaudited	Audited	Audited
1. Income					
a) Revenue from operations	1,816.28	2,412.64	1,909.41	8,596.91	7,798.80
b) Other Income	77.90	116.04	240.43	291.24	529.88
Total income from operations	1,894.18	2,528.68	2,149.84	8,888.15	8,328.68
2. Expenses					
a) Cost of materials consumed	901.75	1,230.82	1,130.96	4,948.01	4,645.84
b) Purchases of stock-in-trade	78.67	20.75	26.26	193.83	84.66
c) Changes in inventories of finished products, work in progress and stock in trade	(124.93)	184.32	171.56	(42.41)	152.61
d) Employee benefit expenses	329.13	292.28	382.54	1,182.43	1,204.10
e) Finance costs	3.36	2.81	6.90	19.62	56.87
f) Depreciation and amortization expense	83.73	79.24	74.87	316.45	311.82
g) Other expenses					
Manufacturing & Operating	106.92	105.04	111.38	427.09	425.80
Others	642.67	355.45	377.31	1,552.38	1,171.35
Total expenses	2,021.29	2,270.71	2,281.78	8,597.40	8,053.05
3. Profit/(Loss) before exceptional items and tax (1-2)	(127.11)	257.97	(131.94)	290.75	275.63
4. Exceptional Items	-	-	-	-	-
5. Profit/ Loss(-) before tax (3+/-4)	(127.11)	257.97	(131.94)	290.75	275.63
6. Tax (Expenses)/ Benefit					
Current tax	(190.00)	-	(125.00)	(190.00)	(125.00)
Deffered Tax	75.48	-	(59.02)	75.48	(59.02)
Tax Related to Earlier Years	9.11	-	15.17	9.11	9.56
7. Profit/ Loss(-) for the period (5-/+6)	(232.52)	257.97	(300.79)	185.34	101.16
8. Other Comprehensive Income					
(i) (a) Items that will not be reclassified to profit or loss	0.31	0.50	(6.73)	2.49	(6.60)
(b) Tax expense/(benefit) on items that will not be reclassified to profit or loss	-	-	-	-	-
(ii) (a) Items that will be reclassified to profit & loss	-	-	-	-	-
(b) Tax expense/(benefit) on items that will be reclassified to profit or loss	-	-	-	-	-
Total Other comprehensive (loss)/ income (net of tax)	0.31	0.50	(6.73)	2.49	(6.60)
9. Total comprehensive income for the period	(232.21)	258.48	(307.52)	187.82	94.57
10. Paid-up equity share capital (Face Value Rs. 10 Each)	2,104.06	2,104.06	2,104.06	2,104.06	2,104.06
11. Other equity (excluding revaluation reserve)				7,933.20	7,745.37
12. Debenture Redemption Reserve					
13. Basic and Diluted Earnings per share after extraordinary items (not annualized)	(1.10)	1.23	(1.46)	0.89	0.45

Notes -

- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, read with rule 3 of the Companies (Indian accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Accounting Rules, 2016
- The Company is operating in the single segment of Drugs & Chemicals.
- The Figures of Previous Year/ Periods may have been regrouped/reclassified/restated wherever necessary.
- Stock Market had crashed in the month of March, 2020. As a result, NAV's of mutual funds had also fallen sharply as on the Balance sheet date resulting in significant loss of fair value of mutual funds amounting to 271.03 lakhs for the quarter ending 31st March, 2020 and 248.87 lakhs for the year ending 31st March, 2020.
- The statement includes the results for the quarter ended 31st March 2020 being the balancing figure between audited figures in respect of the full financial year and the published year to date figure upto the third quarter of the current financial year which were subject to limited review by the auditors.

For ALPA LABORATORIES LIMITED

Megha Neema
MEGHA NEEMA
COMPANY SECRETARY AND COMPLIANCE OFFICER